X4 Pharmaceuticals, a provider and developer of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, closed a $115 million loan facility with Hercules Capital. read more

AUG 7, 2023 - 6:42 am

Hercules Capital named Scott Bluestein chief executive officer and president and elected him to the company’s Board of Directors. Bluestein has served as interim CEO since March 2019. read more

JUL 19, 2019 - 6:55 am

Hercules Capital CEO Manuel Henriquez has voluntarily stepped aside as the firm’s chairman and CEO. According to Bloomberg, the news comes in the wake of Henriquez’s indictment by federal authorities because of his alleged involvement in the college admissions cheating scandal. read more

MAR 14, 2019 - 7:05 am

Hercules Capital Funding Trust 2019-1, an indirect subsidiary of Hercules Capital, issued $250 million in class A notes rated A(sf) by KBRA, backed by approximately $357.2 million of senior secured loans. read more

JAN 23, 2019 - 7:10 am